CEB- Centre of Biological Engineering, University of Minho, Campus of Gualtar, Braga, Portugal.
MITPortugal Program, Lisbon, Portugal.
Curr Med Chem. 2022;29(37):5850-5880. doi: 10.2174/0929867329666220224155037.
An early diagnosis has the potential to greatly decrease cancer mortality. For that purpose, specific cancer biomarkers have been molecularly targeted by aptamer sequences to enable an accurate and rapid detection. Aptamer-based biosensors for cancer diagnostics are a promising alternative to those using antibodies, due to their high affinity and specificity to the target molecules and advantageous production. Synthetic nucleic acid aptamers are generated by in vitro Systematic Evolution of Ligands by Exponential enrichment (SELEX) methodologies that have been improved over the years to enhance the efficacy and shorten the selection process. Aptamers have been successfully applied in electrochemical, optical, photoelectrochemical and piezoelectrical-based detection strategies. These aptasensors comprise a sensitive, accurate and inexpensive option for cancer detection being used as point-of-care devices. This review highlights the recent advances in cancer biomarkers, achievements and optimizations made in aptamer selection, as well as the different aptasensors developed for the detection of several cancer biomarkers.
早期诊断有可能显著降低癌症死亡率。为此,已经通过适体序列对特定的癌症生物标志物进行了分子靶向,以实现准确和快速的检测。与使用抗体的方法相比,基于适体的癌症诊断生物传感器具有很大的优势,因为它们对靶分子具有高亲和力和特异性,并且易于生产。合成核酸适体是通过体外系统进化的配体指数富集(SELEX)方法产生的,这些方法多年来得到了改进,以提高效率并缩短选择过程。适体已成功应用于电化学、光学、光电化学和压电检测策略。这些适体传感器构成了一种敏感、准确和廉价的癌症检测选择,可用作即时检测设备。本综述重点介绍了癌症生物标志物的最新进展、适体选择方面的成就和优化,以及为检测几种癌症生物标志物而开发的不同适体传感器。